Tr1X is developing off-the-shelf type 1 regulatory T cell therapies for difficult-to-treat inflammatory and immune-mediated diseases, with a lead candidate in Phase I/II testing. The program is positioned around inducing long-term immune tolerance using allogeneic Tr1 cells. The company’s approach targets the manufacturing and accessibility challenges that often limit regulatory T cell therapies by creating an off-the-shelf product rather than a patient-specific build. For the field, the early clinical stage is a test case for whether durable tolerance induction can be achieved reliably with standardized allogeneic regulatory-cell manufacturing and dosing strategies.